<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39464360</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1809-9777</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International archives of otorhinolaryngology</Title><ISOAbbreviation>Int Arch Otorhinolaryngol</ISOAbbreviation></Journal><ArticleTitle>Treatments for Olfactory Dysfunction in COVID-19: A Systematic Review.</ArticleTitle><Pagination><StartPage>e728</StartPage><EndPage>e743</EndPage><MedlinePgn>e728-e743</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0044-1786046</ELocationID><Abstract><AbstractText><b>Introduction</b>  Olfactory dysfunction (OD) has emerged as a notable symptom among coronavirus disease 2019 (COVID-19) patients, with its prevalence varying among different populations. Recognizing the need to provide therapeutic solutions for these individuals, the present study seeks to comprehensively review the current evidence on potential underlying mechanisms and treatment modalities to manage OD in COVID-19 patients. <b>Objective</b>  To review the recent evidence on treatments for OD in COVID-19. From the beginning of the study until August 2nd, 2023, we conducted a systematic search on four electronic databases, PubMed, Scopus, Embase, and Web of Science, to find relevant publications. <b>Data Synthesis</b>  In the present study, 37 articles were selected for data extraction and included in the final review. The total number of patients was of 3,560 (2,098 female and 1,462 male subjects). The predominant disorders reported were hyposmia, anosmia, and parosmia. In most of the studies, the pre and postintervention assessments were the same, except for one study, in which the pre-intervention assessment of the disorder was through the SST, Sniffin' Sticks Test (SST), and the post-intervention assessment was through the Visual Analog Scale (VAS) and the 22-item Sinonasal Outcome Test (SNOT-22). The findings suggest olfactory training (OT), ivermectin, palmitoylethanolamide, luteolin, and systemic corticosteroids, in combination with topical corticosteroids, are potential therapies for COVID-19 patients with olfactory impairment. <b>Conclusion</b>  Although the review suggested several medications for OD treatment, further research must delve into the specific impact of OT, a non-pharmacological modality, regarding the mitigation of OD. By continuing to investigate and refine these therapeutic approaches, we can better support COVID-19 patients and improve their quality of life while navigating the challenges posed by OD.</AbstractText><CopyrightInformation>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit ( https://creativecommons.org/licenses/by/4.0/ ).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehraeen</LastName><ForeName>Esmaeil</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4108-2973</Identifier><AffiliationInfo><Affiliation>Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarmohammadi</LastName><ForeName>Soudabeh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzapour</LastName><ForeName>Pegah</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zadeh</LastName><ForeName>Seyed Saeed Tamehri</ForeName><Initials>SST</Initials><AffiliationInfo><Affiliation>Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dehghani</LastName><ForeName>Soheil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molaeipour</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molla</LastName><ForeName>Ayoob</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimi</LastName><ForeName>Elaheh</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbaspour</LastName><ForeName>Faeze</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>SeyedAlinaghi</LastName><ForeName>SeyedAhmad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Int Arch Otorhinolaryngol</MedlineTA><NlmUniqueID>101637652</NlmUniqueID><ISSNLinking>1809-4864</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">anosmia</Keyword><Keyword MajorTopicYN="N">olfactory dysfunction</Keyword></KeywordList><CoiStatement>Conflict of Interests The authors have no conflict of interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39464360</ArticleId><ArticleId IdType="pmc">PMC11511580</ArticleId><ArticleId IdType="doi">10.1055/s-0044-1786046</ArticleId><ArticleId IdType="pii">IAORL-2023-10-1648-SR</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seiden A M. Postviral olfactory loss. Otolaryngol Clin North Am. 2004;37(06):1159–1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563908</ArticleId></ArticleIdList></Reference><Reference><Citation>Welge-Lüssen A, Wolfensberger M. Olfactory disorders following upper respiratory tract infections. Adv Otorhinolaryngol. 2006;63:125–132.</Citation><ArticleIdList><ArticleId IdType="pubmed">16733337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehraeen E, Behnezhad F, Salehi M A, Noori T, Harandi H, SeyedAlinaghi S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. Eur Arch Otorhinolaryngol. 2021;278(02):307–312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297932</ArticleId><ArticleId IdType="pubmed">32556781</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, von Bartheld C S. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist. 2021;27(06):582–603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488171</ArticleId><ArticleId IdType="pubmed">32914699</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito F, Cirillo M, De Micco R et al.Olfactory loss and brain connectivity after COVID-19. Hum Brain Mapp. 2022;43(05):1548–1560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8886650</ArticleId><ArticleId IdType="pubmed">35083823</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, Severini C, Colizza A, De Vincentiis M, La Mantia I. Investigational drugs for the treatment of olfactory dysfunction. Expert Opin Investig Drugs. 2022;31(09):945–955.</Citation><ArticleIdList><ArticleId IdType="pubmed">35983993</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T, Landi D, Liguori C. COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol. 2021;268(04):1171–1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7450256</ArticleId><ArticleId IdType="pubmed">32852580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B KJ, Han R, Zhao J J et al.Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022;378:e069503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>Galougahi M K, Ghorbani J, Bakhshayeshkaram M, Naeini A S, Haseli S. Olfactory bulb magnetic resonance imaging in SARS-CoV-2-induced anosmia: the first report. Acad Radiol. 2020;27(06):892–893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151240</ArticleId><ArticleId IdType="pubmed">32295727</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarz P, Haseli S, Yazdanpanah F, Bagheri F, Raygani N, Karimi-Galougahi M. A systematic review of imaging studies in olfactory dysfunction secondary to COVID-19. Acad Radiol. 2021;28(11):1530–1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8403662</ArticleId><ArticleId IdType="pubmed">34548231</ArticleId></ArticleIdList></Reference><Reference><Citation>Politi L S, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. JAMA Neurol. 2020;77(08):1028–1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">32469400</ArticleId></ArticleIdList></Reference><Reference><Citation>Niesen M, Trotta N, Noel A et al.Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell. Eur J Nucl Med Mol Imaging. 2021;48(06):1890–1901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781559</ArticleId><ArticleId IdType="pubmed">33398411</ArticleId></ArticleIdList></Reference><Reference><Citation>Donegani M I, Miceli A, Pardini M et al.Brain metabolic correlates of persistent olfactory dysfunction after SARS-Cov2 infection. Biomedicines. 2021;9(03):287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7998481</ArticleId><ArticleId IdType="pubmed">33808956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield COVID-19 Genomics Group . Korber B, Fischer W M, Gnanakaran S et al.Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(04):812–8.270000000000001E21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bartheld C S, Hagen M M, Butowt R. The D614G virus mutation enhances anosmia in COVID-19 patients: evidence from a systematic review and meta-analysis of studies from South Asia. ACS Chem Neurosci. 2021;12(19):3535–3549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482322</ArticleId><ArticleId IdType="pubmed">34533304</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes A M, Polidori Let al.Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study Lancet 2022399(10335):1618–1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Bodinier Bet al.Variant-specific symptoms of COVID-19 among 1,542,510 people in England medRxiv 20222022.05. 21.22275368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9651890</ArticleId><ArticleId IdType="pubmed">36369151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T J, Yu A C, Lee J T. Management of post-COVID-19 olfactory dysfunction. Curr Treat Options Allergy. 2022;9(01):1–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8723803</ArticleId><ArticleId IdType="pubmed">35004126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hura N, Xie D X, Choby G Wet al.2020: Wiley Online Library.</Citation></Reference><Reference><Citation>Kattar N, Do T M, Unis G D, Migneron M R, Thomas A J, McCoul E D. Olfactory training for postviral olfactory dysfunction: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2021;164(02):244–254.</Citation><ArticleIdList><ArticleId IdType="pubmed">32660334</ArticleId></ArticleIdList></Reference><Reference><Citation>PRISMA . PRISMA Flow Diagram2020[Available from:http://prisma-statement.org/prismastatement/flowdiagram.aspx</Citation></Reference><Reference><Citation>Page M J, McKenzie J E, Bossuyt P M et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71):n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J AC, Savović J, Page M J et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa:Ottawa Hospital Research Institute. 2011;2(01):1–12.</Citation></Reference><Reference><Citation>Pendolino A L, Ottaviano G, Nijim J et al.A multicenter real-life study to determine the efficacy of corticosteroids and olfactory training in improving persistent COVID-19-related olfactory dysfunction. Laryngoscope Investig Otolaryngol. 2022;8(01):46–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9877766</ArticleId><ArticleId IdType="pubmed">36718474</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepens E JA, Blijleven E E, Boek W M et al.Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial. BMC Med. 2022;20(01):445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667850</ArticleId><ArticleId IdType="pubmed">36384737</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelalim A A, Mohamady A A, Elsayed R A, Elawady M A, Ghallab A F. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial. Am J Otolaryngol. 2021;42(02):102884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836546</ArticleId><ArticleId IdType="pubmed">33429174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, Sekinger B, Wolf S R, Pauli E, Kobal G. ‘Sniffin’ sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22(01):39–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9056084</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocke J, Hopkins C, Philpott C, Kumar N. Is loss of sense of smell a diagnostic marker in COVID-19: A systematic review and meta-analysis. Clin Otolaryngol. 2020;45(06):914–922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436734</ArticleId><ArticleId IdType="pubmed">32741085</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bartheld C S, Hagen M M, Butowt R. Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. ACS Chem Neurosci. 2020;11(19):2944–2961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571048</ArticleId><ArticleId IdType="pubmed">32870641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien J R, Chiesa-Estomba C M, De Siati D R et al.Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(08):2251–2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7134551</ArticleId><ArticleId IdType="pubmed">32253535</ArticleId></ArticleIdList></Reference><Reference><Citation>Saussez S, Vaira L A, Chiesa-Estomba C M et al.Short-Term Efficacy and Safety of Oral and Nasal Corticosteroids in COVID-19 Patients with Olfactory Dysfunction: A European Multicenter Study. Pathogens. 2021;10(06):698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8228154</ArticleId><ArticleId IdType="pubmed">34199734</ArticleId></ArticleIdList></Reference><Reference><Citation>GCCR Group Author . Parma V, Ohla K, Veldhuizen M G et al.More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis. Chem Senses. 2020;45(07):609–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337664</ArticleId><ArticleId IdType="pubmed">32564071</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinosci A, Landis B N, Calmy A. Possible link between anosmia and COVID-19: sniffing out the truth. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head Neck Surg. 2020;277(07):2149–2150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164410</ArticleId><ArticleId IdType="pubmed">32303881</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilinska K, Butowt R. Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular Mechanism. ACS Chem Neurosci. 2020;11(15):2152–2155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467568</ArticleId><ArticleId IdType="pubmed">32673476</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, Borsetto D, Fabbris C et al.Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg. 2020;146(08):729–732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333173</ArticleId><ArticleId IdType="pubmed">32614442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerkin R C, Ohla K, Veldhuizen M Get al.The best COVID-19 predictor is recent smell loss: a cross-sectional studymedRxiv 202014:2020.07.22.201572632020.07.22.</Citation></Reference><Reference><Citation>Vaira L A, Hopkins C, Petrocelli M et al.Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients. Rhinology. 2021;59(01):21–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33290446</ArticleId></ArticleIdList></Reference><Reference><Citation>Helman S N, Adler J, Jafari A et al.Treatment strategies for postviral olfactory dysfunction: A systematic review. Allergy Asthma Proc. 2022;43(02):96–105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8984764</ArticleId><ArticleId IdType="pubmed">35317886</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D H, Kim S W, Kang M, Hwang S H. Efficacy of topical steroids for the treatment of olfactory disorders caused by COVID-19: A systematic review and meta-analysis. Clin Otolaryngol. 2022;47(04):509–515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111649</ArticleId><ArticleId IdType="pubmed">35352483</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P, Camaioni A, Marra P et al.Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells. 2022;11(16):2552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9406356</ArticleId><ArticleId IdType="pubmed">36010630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia D I, Ortiz M, Candela T et al.Design and Evaluation of a Potential Non-Invasive Neurostimulation Strategy for Treating Persistent Anosmia in Post-COVID-19 Patients. Sensors (Basel) 2023;23(13):5880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10346661</ArticleId><ArticleId IdType="pubmed">37447728</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelazim M H, Abdelazim A H, Moneir W. The effect of intra-nasal tetra sodium pyrophosphate on decreasing elevated nasal calcium and improving olfactory function post COVID-19: a randomized controlled trial. Allergy Asthma Clin Immunol. 2022;18(01):67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9354346</ArticleId><ArticleId IdType="pubmed">35927706</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelmaksoud A A, Ghweil A A, Hassan M H et al.Olfactory Disturbances as Presenting Manifestation Among Egyptian Patients with COVID-19: Possible Role of Zinc. Biol Trace Elem Res. 2021;199(11):4101–4108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787876</ArticleId><ArticleId IdType="pubmed">33409924</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, Bernitsas E, La Mantia I et al.Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)? Life (Basel) 2023;13(01):226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9863729</ArticleId><ArticleId IdType="pubmed">36676175</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid R A, Zgair A, Al-Ani R M. Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study. Am J Otolaryngol. 2021;42(05):103033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8024226</ArticleId><ArticleId IdType="pubmed">33839489</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydzewski B, Pruszewicz A, Sulkowski W J. Assessment of smell and taste in patients with allergic rhinitis. Acta Otolaryngol. 2000;120(02):323–326.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, Whitcroft K L, Andrews P et al.Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54(26):1–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29528615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandemirli S G, Altundag A, Yildirim D, Tekcan Sanli D E, Saatci O. Olfactory Bulb MRI and Paranasal Sinus CT Findings in Persistent COVID-19 Anosmia. Acad Radiol. 2021;28(01):28–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571972</ArticleId><ArticleId IdType="pubmed">33132007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A J, Lee A CY, Chu H et al.Severe Acute Respiratory Syndrome Coronavirus 2 Infects and Damages the Mature and Immature Olfactory Sensory Neurons of Hamsters. Clin Infect Dis. 2021;73(02):e503–e512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454453</ArticleId><ArticleId IdType="pubmed">32667973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono R, Arita R, Takayama S et al.Kampo medicine promotes early recovery from coronavirus disease 2019-related olfactory dysfunction: a retrospective observational study. Front Pharmacol. 2022;13:844072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006147</ArticleId><ArticleId IdType="pubmed">35431935</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires ÍAT, Steffens S T, Mocelin A G et al.Intensive olfactory training in post-COVID-19 patients: a multicenter randomized clinical trial. Am J Rhinol Allergy. 2022;36(06):780–787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309586</ArticleId><ArticleId IdType="pubmed">35866202</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid R A, Zgair A, Al-Ani R M. Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study. Am J Otolaryngol. 2021;42(05):103033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8024226</ArticleId><ArticleId IdType="pubmed">33839489</ArticleId></ArticleIdList></Reference><Reference><Citation>Saussez S, Vaira L A, Chiesa-Estomba C M et al.Short-Term Efficacy and Safety of Oral and Nasal Corticosteroids in COVID-19 Patients with Olfactory Dysfunction: A European Multicenter Study. Pathogens. 2021;10(06):698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8228154</ArticleId><ArticleId IdType="pubmed">34199734</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepens E JA, Blijleven E E, Boek W M et al.Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial. BMC Med. 2022;20(01):445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667850</ArticleId><ArticleId IdType="pubmed">36384737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F, Azar C, Goektas O.Treatment of Olfactory Disorders After SARS - CoViD 2 Virus Infection Ear Nose Throat J 2023•••1455613231168487</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10051008</ArticleId><ArticleId IdType="pubmed">36976171</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh C V, Jain S, Parveen S. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients. Am J Otolaryngol. 2021;42(03):102892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972940</ArticleId><ArticleId IdType="pubmed">33493729</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaira L A, Hopkins C, Petrocelli M et al.Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients. Rhinology. 2021;59(01):21–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33290446</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandersteen C, Payne M, Dumas L-É et al.Olfactory training in post-COVID-19 persistent olfactory disorders: value normalization for threshold but not identification. J Clin Med. 2022;11(12):3275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9224948</ArticleId><ArticleId IdType="pubmed">35743346</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaylacı A, Azak E, Önal A, Aktürk D R, Karadenizli A. Effects of classical olfactory training in patients with COVID-19-related persistent loss of smell. Eur Arch Otorhinolaryngol. 2023;280(02):757–763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9335450</ArticleId><ArticleId IdType="pubmed">35904631</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>